Thanks. Here's the relevant quote from the article brentle found:

Quote:

---

The biotech gave no hint as to the specific concerns that were raised from the data, only adding that it would now review the data “to understand the DSMB’s rationale for their recommendation.”

---

So they won't even tell us what the problem was. Must have been bad -- if it had been minor, they would have said so.